

during the same time frame is beyond the scope of this observational study.

Our study highlights the fact that isoprostane concentrations have the same limitations as other measures of obstetric outcome, such as pH and Apgar score: i.e., they are increased in neonates with HIE, but may also be increased in apparently healthy infants and may be within reference values in infants who die from acute causes or in whom a pathology manifests after delivery.

We are grateful to all medical and nursing staffs in the labor wards and neonatal units at Prince of Wales Hospital, The First Affiliation Hospital of Medical College of Jinan University, and The Women's & Children's Hospital of Guangdong Province for case recruitment and sample collection. The study was supported by the Hong Kong Special Administration Region Research Grant Council (CUHK4329/99M). All contributors and guarantors in this study are independent from the funding agency, and the views expressed here are those of the authors. This report was partially awarded (Asian-Pacific Congress of Clinical Biochemistry Regional Service Award) and represented at the 10th Asian-Pacific Congress of Clinical Biochemistry and 42nd Annual Scientific Conference of the Australasian Association of Clinical Biochemists in Perth, Australia, during September 2004.

## References

- Ferguson SD, Gehrke T. Deaths related to intrapartum asphyxia. Audit in one unit found neonatal care to be suboptimal at weekends [Letter]. *BMJ* 1998;316:1318-9.
- Macintosh M, Lee C. Deaths related to intrapartum asphyxia. Intrapartum death rates in England 1993-5 did not show consistent peaks or troughs [Letter]. *BMJ* 1998;316:1319.
- Murphy DJ. Deaths related to intrapartum asphyxia. Denominators are needed before conclusions can be drawn [Letter]. *BMJ* 1998;316:1319.
- Lucas M, Thomson A, Aird I. Deaths related to intrapartum asphyxia. Consultant expansion in obstetrics and gynaecology is not fast enough [Letter]. *BMJ* 1998;316:1319.
- Bastian H, Keirse MJNC, Lancaster PAL. Perinatal death associated with planned home birth in Australia: population based study. *BMJ* 1998;317:384-8.
- Barela TD, Johnson JD, Hayek A. Metabolic acidosis in the newborn period. *Clin Endocrinol Metab* 1983;12:429-46.
- Low JA, Panagiotopoulos C, Derrick EJ. Newborn complications after intrapartum asphyxia with metabolic acidosis in the term fetus. *Am J Obstet Gynecol* 1994;170:1081-7.
- Socol ML, Garcia PM, Riter S. Depressed Apgar scores, acid-base status, and neurologic outcome. *Am J Obstet Gynecol* 1994;170:991-9.
- Rogers MS, Wang W, Mongelli M, Pang CP, Duley JA, Chang AMZ. Lipid peroxidation in cord blood at birth: a marker of fetal hypoxia during labour. *Gynecol Obstet Invest* 1997;44:229-33.
- Wang CC, Rogers MS. Lipid peroxides in cord blood: the effects of umbilical nuchal cord. *Br J Obstet Gynaecol* 1997;104:251-5.
- Liu BY, Wang CC, Lau TK, Chu CY, Pang CP, Rogers MS, et al. Meconium stained liquor (MSL) during labor is associated with raised neonatal cord blood 8-iso-prostaglandin F<sub>2α</sub> concentration. *Am J Obstet Gynecol* 2004;192:289-94.
- Mongelli JM, Wang CC, Wang W, Pang CCP, Rogers MS. Oxygen free radical activity in the second stage of labor. *Acta Obstet Gynecol Scand* 1997;76:765-8.
- Rogers MS, Mongelli JM, Tsang KH, Wang CC, Law KP. Lipid peroxidation in cord blood at birth: the effect of labour. *Br J Obstet Gynaecol* 1998;105:739-44.
- Wang W, Pang CC, Rogers MS, Chang AMZ. Lipid peroxidation in cord blood at birth. *Am J Obstet Gynecol* 1996;174:62-5.
- Hoffman SW, Rzigalinski BA, Willoughby KA, Ellis EF. Astrocytes generate isoprostanes in response to trauma or oxygen radicals. *J Neurotrauma* 2000;17:415-20.
- Rogers MS, Chang AMZ. Perinatal asphyxia: a Bayesian analysis of prediction and prevention. *J Obstet Gynaecol* 1991;11:34-40.
- Rogers MS, Murray HG, Wang CC, Pennell CE, Turner A, Yan P, et al. Oxidative stress in the fetal lamb brain following intermittent umbilical cord occlusions: a path analysis. *Br J Obstet Gynaecol* 2001;108:1283-90.

DOI: 10.1373/clinchem.2004.047241

**Comparison of a Fully Automated Immunoassay with a Point-of-Care Testing Method for B-Type Natriuretic Peptide**, Concetta Prontera, Simona Storti, Michele Emdin, Claudio Passino, Luc Zyww, Gian Carlo Zucchelli, and Aldo Clerico\* (Consiglio Nazionale delle Ricerche Institute of Clinical Physiology, Pisa, Italy; \* address correspondence to this author at: Laboratory of Cardiovascular Endocrinology and Cellular Biology, CNR Institute of Clinical Physiology, Via Trieste 41, 56125 Pisa, Italy; fax 39-0585-493601, e-mail clerico@ifc.cnr.it)

The clinical relevance of B-type natriuretic peptide (BNP) as a diagnostic tool and prognostic marker in patients with cardiovascular diseases has been confirmed recently (1-3). Over the last 5 years, several immunoassay methods for the measurement of BNP, which share some analytical characteristics, such as full automation, turn-around time <60 min, lower imprecision, and/or better analytical and functional sensitivity, have become commercially available (1, 4). The analytical performance and diagnostic accuracy of immunoassays for BNP were compared recently (5, 6). In the present study, we evaluated the analytical performance and diagnostic accuracy of an automated immunochemiluminescent assay for BNP (ACCESS System; Beckman Coulter). We also compared its performance and accuracy with the TRIAGE BNP test (Biosite). The 2 immunoassays use as antigen the intact BNP 1-32 peptide and the same mouse anti-human BNP antibodies. The capture antibody (Scios) recognizes the peptide ring, whereas the detection antibody (Biosite) recognizes an epitope between amino acids 5 and 10 at the NH<sub>2</sub> terminus (6, 7). All statistical analyses were performed by use of parametric tests after log transformation of the original data. Nonparametric tests were also performed and showed identical statistical trends.

We collected blood samples from 91 healthy individuals [51 women and 40 men; mean (SD) age, 43.2 (13.4) years; range, 16-71 years] and 214 patients with idiopathic or secondary cardiomyopathy (only 21 with a left ventricular ejection fraction >50%). Blood was collected between 0800 and 0900 after the individuals had fasted overnight and had rested for 20 min in a supine position. Immediately after withdrawal, blood samples (8-10 mL) were placed in ice-chilled disposable polypropylene tubes containing EDTA (1 mg/mL of plasma). Plasma samples were obtained shortly after venipuncture by centrifugation for 15 min at 4 °C and then were frozen and stored at -20 °C in 0.5-mL aliquots until being assayed.

We found that plasma samples can be kept at 37 °C for




Fig. 1. Total imprecision profiles (A) and Bland-Altman difference plot (B) for the tested immunoassays.

(A), the CV values corresponding to desirable imprecision (15% CV) and optimum imprecision (10% CV), respectively, are indicated with dashed lines. (B), the difference plot shows the difference between methods as a percentage (y axis) plotted vs the mean value (x axis). Solid horizontal lines indicate the mean difference and the  $\pm 3$  SD values. The dashed line indicates no difference.

4 h without a significant decrease in measured (on an ACCESS system) BNP concentration [mean (SD) measured value, 97.8 (5.3)% of the original concentration; mean difference from the original concentration, 10.3 ng/L; 95% confidence interval (CI), -20.4 to 41.1 ng/L ( $P = 0.1147$ ); median measured value, 790 ng/L (range, 37–2904 ng/L);  $n = 15$ ]. We observed a slight but significant difference when plasma samples were kept at 4 °C for 24 h [mean measured value 89.0 (5.0)% of the original concentration; mean difference from the original concentration, 27.5 ng/L; 95% CI, 13.7–41.4 ng/L ( $P < 0.0001$ ); median measured value, 160.5 ng/L (range, 12–824 ng/L);  $n = 24$ ].

We assessed the detection limit of the ACCESS by repeatedly measuring ( $n = 20$ ) the calibrator with a BNP concentration of 0 ng/L in 3 different runs. The mean (SD) measured concentration was 0.3 (0.1) ng/L (range, 0.3–0.4 ng/L). We confirmed the results of a previous study from our laboratory indicating that the detection limit of the TRIAGE is  $< 8$  ng/L (manufacturer-reported detection limit, 5 ng/L) (8). The imprecision profiles of the TRIAGE and ACCESS, obtained by repeated measurements over

20 different days of several plasma samples (7 on the TRIAGE and 12 on the ACCESS) with BNP concentrations covering the analytical working range, are shown in Fig. 1A. According to the IFCC goals for desirable (15% total CV) and optimum (10% total CV) imprecision (7), the 2 methods had similar functional sensitivities ( $\sim 10$  ng/L and 30 ng/L, respectively). The imprecision for samples with BNP values  $< 10$  ng/L was not satisfactory in either method. We assessed the within-run and total imprecision of the ACCESS according to the NCCLS EP5-A guideline (including experimental protocol, number of measurements, and data calculation) (9) by repeatedly assaying 2 plasma samples with BNP concentrations of 52.6 and 1095 ng/L in duplicate on 20 different working days (both in the morning and in the afternoon). For the 2 samples, within-run imprecision was 3.4% and 1.6%, respectively, and total imprecision was 8.4% and 5.9%.

After exclusion by statistical analysis of the 17 samples with BNP values  $< 5$  ng/L in the TRIAGE assay, we found a close linear relationship ( $R = 0.919$ ;  $n = 287$ ) between the 2 methods: ACCESS = 62.5 (14.1) + 0.932 (0.024) TRIAGE ( $P < 0.0001$  for both). The Bland-Altman plot of the same data confirmed that there was a difference between the values measured with the 2 immunoassays; this difference increased proportionally as the measured concentration increased (Fig. 1B) (10). There was a slight but significant mean difference between the values [mean (SD) difference for TRIAGE – ACCESS, -45.2 (217.8) ng/L (minimum–maximum, -1152 to 1667 ng/L;  $P < 0.0001$ ); mean % difference, -0.2% (minimum–maximum, -2.0% to 1.7%)].

All 91 healthy persons were nonobese, normotensive, and free from acute or chronic diseases. Moreover, all had values within the reference intervals for creatinine, urea, glucose, uric acid, albumin, electrolytes, cardiac markers, and hemoglobin as well as for erythrocyte and leukocyte

Table 1. Characteristics of the heart failure patients enrolled for the evaluation of diagnostic accuracy.

|                                                            | NYHA class |          |          |
|------------------------------------------------------------|------------|----------|----------|
|                                                            | All        | I-II     | III-IV   |
| No. of patients                                            | 193        | 122      | 71       |
| Mean (SD) age, years                                       | 64 (13)    | 62 (13)  | 67 (12)  |
| F/M, n                                                     | 45/148     | 28/94    | 16/55    |
| Mean (SD) BMI, <sup>a</sup> kg/m <sup>2</sup>              | 26 (4)     | 27 (2)   | 25 (3)   |
| Idiopathic/postischemic/<br>secondary cardiomyopathy,<br>% | 49/36/15   | 57/26/17 | 37/51/12 |
| Mean (SD) LVEF, %                                          | 34 (10)    | 37 (11)  | 27 (7)   |
| Diabetes, %                                                | 14         | 11       | 18       |
| Treatment, %                                               |            |          |          |
| Furosemide                                                 | 84         | 36       | 75       |
| Beta-blockers                                              | 71         | 64       | 79       |
| ACE inhibitor                                              | 78         | 79       | 77       |
| ARB                                                        | 7          | 4        | 12       |
| Spironolactone                                             | 32         | 16       | 59       |

<sup>a</sup> BMI, body mass index; LVEF, left ventricular ejection fraction; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.

counts and basic urine analysis. All were asymptomatic and underwent a complete examination by a cardiologist, including a visit, standard 12-lead electrocardiogram, Doppler echocardiographic examination, and a bicycle stress test (when older than 50 years), which excluded silent heart disease. The median ACCESS and TRIAGE BNP concentrations were 10.5 ng/L (range, 1–53 ng/L; 97.5th percentile, 45 ng/L) and 8.9 ng/L (range <5 to 52 ng/L; 97.5th percentile, 35 ng/L), respectively. The distribution of BNP values measured by the 2 methods in the healthy group is shown in Fig. 1 of the Data Supplement that accompanies this Technical Brief at <http://www.clinchem.org/content/vol51/issue7/>.

To evaluate the diagnostic accuracy of the 2 methods, we measured only samples from the 193 patients with a clinically ascertained diagnosis of heart failure. The clinical characteristics of these patients are reported in Table 1. Cardiac morphology and function were assessed by 2-dimensional echocardiography, or cardiac catheterization when needed. The median (range) ACCESS and TRIAGE BNP concentrations measured were 171 (2–4833) ng/L and 118 (<5 to 4930) ng/L, respectively. The distributions of BNP values measured by the 2 methods in these patients grouped according to the severity of heart failure [New York Heart Association (NYHA) functional classes I to IV] are shown in Figs. 1 and 2 of the online Data Supplement. However, the results obtained with both the TRIAGE and ACCESS indicated a significant difference between the mean BNP values in healthy persons vs heart failure patients ( $P < 0.0001$  by Scheffé test after ANOVA).

We used ROC curve analysis to evaluate the diagnostic accuracy of the 2 methods in differentiating between healthy persons and patients with heart failure. We found no difference in diagnostic accuracy between the 2 methods for differentiating healthy persons from patients with mild (NYHA class I and II;  $n = 122$ ;  $P = 0.196$ ) or severe (NYHA class III and IV;  $n = 71$ ;  $P = 0.697$ ) heart failure. For the TRIAGE, the areas under the curves were 0.840 (SE, 0.027; 95% CI, 0.788–0.893) for patients with mild disease and 0.998 (SE, 0.002; 95% CI, 0.995–1.000) for patients with severe heart failure, whereas for the ACCESS system, the areas under the curves were 0.870 (SE, 0.023; 95% CI, 0.825–0.916) for patients with mild disease and 0.997 (SE, 0.002; 95% CI, 0.993–1.000) for patients with severe heart failure. The BNP values corresponding to a sensitivity of 95% in differentiating healthy persons from patients with mild heart failure were 7.5 ng/L (corresponding specificity, 40%) for the ACCESS and 5.1 ng/L for the TRIAGE (corresponding specificity, 29%). The BNP values corresponding to a specificity of 95% were 41 ng/L (corresponding sensitivity, 65%) for the ACCESS and 29 ng/L (corresponding sensitivity, 63%) for the TRIAGE (Fig. 3 of the online Data Supplement). However, it is important to emphasize that the 95% sensitivity with the TRIAGE was obtained at a cutoff near the assay detection limit. The decision cutoff values from the current study are strictly related to our specific clinical setting, comparing healthy persons and patients with clinically ascertained heart failure. In routine clinical

practice, several groups of individuals/patients suspected of having a specific disease are usually compared.

The present data confirm and extend previous results suggesting that BNP results are method dependent and that a single predefined common cutoff value cannot be used (5, 6). Furthermore, we demonstrated that immunoassays that use the same antibodies and calibration materials do not automatically give the same results. However, the cutoff and reference values of these 2 methods are similar.

## References

1. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review [Review]. *Clin Chem* 2004;50:33–50.
2. Galvani M, Ferrini D, Ottani T. Natriuretic peptides for risk stratification of patients with acute coronary syndromes [Review]. *Eur J Heart Fail* 2004;6:327–33.
3. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. *Arch Intern Med* 2004;164:1978–84.
4. Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods [Review]. *Clin Chem* 2000;46:1529–34.
5. Clerico A, Prontera C, Emdin M, Passino C, Storti S, Poletti R, et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP. *Clin Chem* 2005;51:445–7.
6. Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. *Am J Clin Pathol* 2005;123:439–45.
7. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AHB, Tate J, et al., on behalf of the Committee on Standardization of Markers of Cardiac Damage of the IFCC. Quality specifications for B-type natriuretic peptide assays. *Clin Chem* 2005;51:486–93.
8. Storti S, Prontera C, Emdin M, Passino C, Prati P, Fontani G, et al. Analytical performance and clinical results of a fully automated MEIA system for BNP assay: comparison with a POCT method. *Clin Chem Lab Med* 2004;42:1178–85.
9. National Committee for Clinical Laboratory Standards. Evaluation of precision performances of clinical chemistry devices: approved guideline. NCCLS Document EP5-A, Vol. 19, No 2. Wayne, PA: NCCLS, February 1999:1–43.
10. Bland JM, Altman DG. Applying the right statistics: analysis of measurement studies. *Ultrasound Obstet Gynecol* 2003;22:85–93.

DOI: 10.1373/clinchem.2005.048496

**Invasive Trophoblast Antigen (Hyperglycosylated Human Chorionic Gonadotropin) as a First-Trimester Serum Marker for Down Syndrome, Martin J.N. Weinans,<sup>1\*</sup> Ulrich Sancken,<sup>2</sup> Raj Pandian,<sup>3</sup> Jody M.W. van de Ouweland,<sup>4</sup> Henk W.A. de Bruijn,<sup>4</sup> Jozien P. Holm,<sup>1</sup> and Albert Mantingh<sup>1</sup>**  
(<sup>1</sup> Antenatal Diagnosis Unit, Department of Obstetrics and Gynaecology, and <sup>4</sup> Department of Pathology and Laboratory Medicine, University Hospital, Groningen, The Netherlands; <sup>2</sup> Institut für Humangenetik der Universität Göttingen, Göttingen, Germany; <sup>3</sup> Quest Diagnostics Nichols Institute, San Juan Capistrano, CA; \* address correspondence to this author at: Department of Obstetrics and Gynaecology, University Hospital, PO Box 30.001, 9700 RB Groningen, The Netherlands; fax 31503611806, e-mail martinweinans@planet.nl)

Hyperglycosylated human chorionic gonadotropin (hCG) is a variant of hCG with more asparagine (N)-linked